Radiolabelled octreotate analogues as PET tracers

US10201625B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10201625-B2
Application numberUS-201214002168-A
CountryUS
Kind codeB2
Filing dateMar 1, 2012
Priority dateMar 1, 2011
Publication dateFeb 12, 2019
Grant dateFeb 12, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).

First claim

Opening claim text (preview).

What is claimed is: 1. A 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue of formula (5b): wherein: R 2 has the following structure: 2. The 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue according to claim 1 , wherein, R 2 is: 3. A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically acceptable carrier, excipient, or biocompatible carrier. 4. An alkyne linked [Tyr 3 ]octreotate analogue of formula (5a): wherein: R 1 is R 2 has the following structure: 5. The alkyne linked [Tyr 3 ]octreotate analogue according to claim 4 , wherein R 2 is: 6. A method of making the 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue of claim 1 ; the method comprising the step of reacting an alkyne linked [Tyr 3 ]Octreotate analogue having the formula (5a): with 2-[ 18 F]Fluoroethylazide under copper catalyzed click chemistry conditions to form the corresponding 2-[ 18 F]fluoroethyl triazole linked [Tyr 3 ]octreotate analogue having the formula (5b) in claim 1 ; wherein: R 1 in formula (5a) is  and R 2 in formula (5a) has the following structure: 7. A method of imaging comprising the steps of administering a compound of claim 1 to a subject and detecting said compound in said subject. 8. The method of detecting neuroendocrine tumor(s) in vivo in a subject comprising the steps of: (i) administering to said subject a compound of claim 1 or a pharmaceutical composition thereof; (ii) allowing said compound or pharmaceutical composition thereof to bind to somatostatin receptor(s) found on the surface of the neuroendocrine tumour(s) in said subject; (iii) detecting signals emitted by the radioisotope in said compound or pharmaceutical composition thereof on said neuroendocrine tumor(s) in said subject; (iv) generating an image representative of the location and/or amount of said signals; and, optionally, (v) determining the distribution and extent of said neuroendocrine tumour(s) in said subject. 9. The method of detecting lung tumor(s) in vivo in a subject comprising the steps of: (i) administering to said subject a compound of claim 1 or a pharmaceutical composition thereof; (ii) allowing said compound or pharmaceutical composition thereof to bind to somatostatin receptor(s) found on the surface of the lung tumour(s) in said subject; (iii) detecting signals emitted by the radioisotope in said compound or pharmaceutical composition thereof on said lung tumor(s) in said subject; (iv) generating an image representative of the location and/or amount of said signals; and, optionally, (v) determining the distribution and extent of said lung tumour(s) in said subject.

Assignees

Inventors

Classifications

  • Peptides; Proteins · CPC title

  • A61K51/083Primary

    the peptide being octreotide or a somatostatin-receptor-binding peptide · CPC title

  • Heterocyclic compounds · CPC title

  • conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title

  • A61K51/08Primary

    Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10201625B2 cover?
Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreati…
Who is the assignee on this patent?
Luthra Sajinker Kaur, Leyton Julius, Aboagye Eric Ofori, and 6 more
What technology area does this patent fall under?
Primary CPC classification A61K51/083. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).